Alzheimer's disease(AD)is a progressive degenerative disease of the central nervous system.Lecanemab is a humanized IgG1 monoclonal antibody that preferentially targets soluble amyloid β-protein aggregates and can slow down the progression of AD.In January 2023,the U.S.Food and Drug Administration approved lecanemab to treat AD patients with mild cognitive impairment or mild dementia stage of disease.The common adverse drug reactions of lecanemab were infusion-related reactions,headache,and amyloid-related imaging abnormalities with edema.The mechanism of action,pharmacokinetics,clinical research,economic evaluation,and safety evaluation of lecanemab were reviewed in this article,so as to provide reference for rational clinical drug use.
万方数据
维普
